Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $161K fell 35.9% year over year, behind the -21.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 13.4% from the prior quarter. Over 3 fiscal years it compounded at +18.0% a year.

Context

  • Depreciation & amortization amounted to 55.1% of revenue in FY2025, down 44.9 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -35.9% toward the trailing-twelve-month pace of -21.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$161K-13.4% QoQ
Last fiscal yearDec 2025
$900K-12.5% YoY
LTMMar 2026
$810K-21.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-35.9%——
1 year-12.5%——
3-year CAGR+18.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
900K USD
Year-over-year change
-12.5%
4-year CAGR
+16.0%

Depreciation & Amortization vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -21.4% is the 6th highest of 9, against a peer median of +3.7%.
  • Depreciation & amortization amounts to 25.6% of revenue for RANI, versus a peer median of 19.0%.
RANI Competitors
Depreciation & Amortization for RANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$6.56M USD-25.2%-14.4%19.0%
IPHAInnate Pharma S.A.FY2025€5.09M EUR+155.3%-51.8%182.7%
MOLNMolecular Partners AGLTM Mar 2026CHF 2.61M CHF+9.7%-3.5%—
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$1.99M USD-26.5%+15.4%11.3%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$1.14M USD-2.3%+2.2%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$1.03M USD+94.7%+56.5%196.6%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$810K USD-21.4%+18.0%25.6%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$248K USD-57.2%-46.1%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$143K USD+37.5%+8.6%8.0%
Peer median (excluding RANI) —+3.7%-0.7%19.0%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.72M001.03M1.63M
Cost of Revenue00822K0900K
Gross Profit2.72M0(822K)1.03M733K
Gross Margin100.0%——100.0%44.9%
Research & Development26.48M36.61M39.62M26.68M20.21M
Selling, General & Admin27.83M26.84M26.48M23.95M19.74M
Operating Expenses54.32M63.45M65.28M54.34M39.04M
Depreciation & Amortization497K548K822K1.03M900K
EBITDA(52.08M)(61.66M)(61.98M)(50.52M)(37.16M)
EBITDA Margin-1917.0%——-4914.7%-2275.5%
Operating Income(51.6M)(63.45M)(66.1M)(53.31M)(38.31M)
Operating Margin-1899.1%——-5186.2%-2346.0%
Interest Income89K1.25M3.3M1.76M827K
Interest Expense466K1.07M5.09M5.03M2.89M
Other Income / Expenses(1.45M)177K(1.78M)23.3M(2.64M)
Income Before Tax(53.05M)(63.27M)(67.88M)(30.02M)(40.95M)
Pre-Tax Margin-1952.4%——-2920.0%-2507.7%
Income Tax Expense41K70K026.57M0
Net Income(8.33M)(30.59M)(33.97M)(30.02M)(29.67M)
Net Margin-306.6%——-2920.0%-1817.1%
EPS (Basic)(0.42)(1.28)(1.33)(1.05)(0.45)
EPS (Diluted)(0.42)(1.28)(1.33)(1.05)(0.45)
Weighted Avg Shares19.53M23.82M25.51M28.48M66.14M
Weighted Avg Shares (Diluted)19.53M23.82M25.51M28.48M66.14M

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.